Veru Inc (VERU) Stock Price, Quote & News

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to preven...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 509 6897

Website: verupharma.com

Address:

2916 North Miami Avenue, Suite 1000, Miami, United States

mrkymrk Oct. 25 at 1:44 PM

$VERU well we will know something by the second week of Nov which is when VERU typically reports earnings. (Or lack therof) If Steiner carries the same message this thing will crater to the ground.

0 · Reply

StockGoing Oct. 24 at 2:21 PM

$VIVK $CERO $ASST $VERU 🔥🔥🔥

0 · Reply

Ljkjr Oct. 23 at 10:37 PM

$VERU Corrected post: It is likely VERU is being shorted by posters on in this blog. You can’t trust anyone on chat boards because for one reason strategies change relative to a stock’s performance and a poster’s portfolio. Big Pharm could be teaming against us too. But I am still optimistic about the data; and some kind of deal being made soon. I have been wrong before. I’ll ride it out—maybe into the sunset.

0 · Reply

Ljkjr Oct. 23 at 8:58 PM

$VERU It has likely been a short attack. You can’t trust anyone one chat boards. Big Pharm could be teaming against us too. But I am still optimistic that about the data and some kind of deal being made soon. I have been wrong before. I’ll ride it out—maybe into the sunset.

1 · Reply

mrkymrk Oct. 23 at 7:38 PM

$VERU total clown show

0 · Reply

HoHoHoHum Oct. 23 at 7:17 PM

$VERU is this going to ever come back? Or is this another case of slipping into the BK territory? I would be sad to see the latter happen but so many bios have disappeared into oblivion in the last 3 years.

0 · Reply

Eesnimi Oct. 23 at 4:16 PM

$VERU All time low coming. Why not

0 · Reply

PennyConnection1 Oct. 23 at 2:55 PM

$VERU ladies and germs

0 · Reply

BioRich Oct. 23 at 2:57 AM

$ALT $VERU I love it when my biggest stalker tries to bash me and my picks, only to fall on their face... yet again. Thanks @Turribull for trying to get cute with $VERU. Great company with near ZERO lean mass when added to Wegovy. $VERU is another $ALT killer. In a turn of beautiful fortune, $VERU proceeded to gain 4.7% from the time of your ill-advised bash attempt. Oh, and $ALT went down 2.5%. So that means your EE is 8.2% on your embarrassing post. *EE - Effective Embarrassment For those looking to make money and not just join bagholding misery cults... Follow/ Subscribe for more suggestions and perspective. Would love to hear yours. Let's make some money. Cheers!

1 · Reply

cray1965 Oct. 22 at 9:40 PM

$VERU I get it — Veru’s history is ugly, no argument there. They’ve pivoted more than once and burned a lot of trust along the way. But calling it a scam is a bit much. And I don't work for Veru, and could just as easily call you a short seller. Enobosarm is real science with peer-reviewed data showing it builds muscle and improves function. The FDA literally gave them the green light for the next trial design (72 weeks, tirzepatide combo), and they just added Dr. Stefan Anker — one of the biggest names in muscle preservation — to the advisory board. That’s not what scam companies do. Yeah, management has made mistakes, but I’m buying the drug, not the drama. The molecule works — and if it does in the next trial what it’s already shown before, any big pharma would want it. That’s where the real value is. Believe what you want, but facts > feelings.

1 · Reply

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Aug 12, 2025, 12:57 PM EDT - 2 months ago

Veru Inc. (VERU) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 6:30 AM EDT - 2 months ago

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Aug 11, 2025, 8:30 AM EDT - 2 months ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Aug 6, 2025, 8:30 AM EDT - 2 months ago

Veru Announces Reverse Stock Split

Jul 22, 2025, 8:30 AM EDT - 3 months ago

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Jun 11, 2025, 8:30 AM EDT - 4 months ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

May 28, 2025, 12:11 PM EDT - 5 months ago

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

May 28, 2025, 6:30 AM EDT - 5 months ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 26, 2025, 9:36 PM EDT - 5 months ago

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 8, 2025, 12:42 PM EDT - 6 months ago

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025, 9:30 AM EDT - 6 months ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:25 AM EDT - 6 months ago

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 6:30 AM EDT - 6 months ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 1, 2025, 8:30 AM EDT - 6 months ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Apr 16, 2025, 8:30 AM EDT - 6 months ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Mar 31, 2025, 8:30 AM EDT - 7 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Feb 19, 2025, 10:41 AM EST - 8 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 13, 2025, 2:35 PM EST - 9 months ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 6:30 AM EST - 9 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Jan 27, 2025, 10:34 AM EST - 9 months ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 6:30 AM EST - 9 months ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Dec 31, 2024, 8:30 AM EST - 10 months ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Nov 26, 2024, 8:30 AM EST - 11 months ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 5, 2024, 8:30 AM EST - 1 year ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Aug 10, 2024, 8:39 AM EDT - 1 year ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 17, 2024, 4:45 PM EDT - 1 year ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Steven B. Heymsfield M.D.

May 14, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the GLP-1 Based Therapeutics Summit

May 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Veru Reschedules Annual Meeting of Shareholders

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Feb 27, 2024, 7:15 PM EST - 1 year ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 20, 2024, 8:30 AM EST - 1 year ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 8, 2024, 1:36 PM EST - 1 year ago

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

mrkymrk Oct. 25 at 1:44 PM

$VERU well we will know something by the second week of Nov which is when VERU typically reports earnings. (Or lack therof) If Steiner carries the same message this thing will crater to the ground.

0 · Reply

StockGoing Oct. 24 at 2:21 PM

$VIVK $CERO $ASST $VERU 🔥🔥🔥

0 · Reply

Ljkjr Oct. 23 at 10:37 PM

0 · Reply

Ljkjr Oct. 23 at 8:58 PM

1 · Reply

mrkymrk Oct. 23 at 7:38 PM

$VERU total clown show

0 · Reply

HoHoHoHum Oct. 23 at 7:17 PM

0 · Reply

Eesnimi Oct. 23 at 4:16 PM

$VERU All time low coming. Why not

0 · Reply

PennyConnection1 Oct. 23 at 2:55 PM

$VERU ladies and germs

0 · Reply

BioRich Oct. 23 at 2:57 AM

1 · Reply

cray1965 Oct. 22 at 9:40 PM

1 · Reply

Samspoti Oct. 22 at 11:10 AM

$VERU been a bit since Ive looked at this board. It’s as delusional as it’s ever been. This company went from treating cancer to covid to respiratory illnesses and now to weight loss. This is the biggest scam company and Im almost convinced the pumpers here are employed by veru. Sabi is a trash drug and its been around for a decade … of failures. Fireside chats, new board hires, small clinical trials…dont buy into this garbage stock! And certainly dont buy what these loyalists are pumping. I used to belong to a facebook group dedicated to this stock. Trust me, scam company.

1 · Reply

MrVeryNiceGuy Oct. 22 at 5:15 AM

$VERU Now that all the adjusted options expired they will likely get a call from the market maker allowing them to release the PR

0 · Reply

cray1965 Oct. 21 at 8:33 PM

$VERU Anybody find it a coincidence that Lilly stopped their (more expensive) Bimagrumab T2D trial in June, right around the time of Veru's full phase 2 results, then officially terminated in Sept, a couple of days after Veru's eop2 meeting. Bimagrumab becomes basically obsolete(or lower priority) if you expect to have an oral muscle retention option.

1 · Reply

PennyConnection1 Oct. 21 at 2:57 PM

$VERU

0 · Reply

mrkymrk Oct. 21 at 1:54 PM

$VERU They also added another member to their scientific advisory board. Dr Stefan Anker from Germany.

2 · Reply

mrkymrk Oct. 20 at 9:43 PM

$VERU the corporate presentation does not reference “pending additional funding” on their planned trial. A comment that was on all previous footnotes.

2 · Reply

mrkymrk Oct. 20 at 1:54 PM

$VERU I hear your points cray but now listening to Steiner on his latest water tower podcast, he seems to indicate that they are running this small phase 2B in order to attract the big boys. Which implies that they have no current traction. Ie No NDA’s have been signed. Thoughts?

3 · Reply

cray1965 Oct. 20 at 1:52 AM

$VERU (continued) 6. Veru(despite what they say) can’t(and shouldn’t) fund Phase2b and any big pharma that is interested wouldn’t want them to with such a small delta determining phase 3. 7.Roche/Regeron/Astrazenca /Phizer and others, desperate to get into the GLP gold rush. are largely boxed out by Novo and Lilly. Obtaining a muscle retention drug is a back door way of getting in. 8. Lilly has a small molecule GLP, and is increasing manufacturing capacity. Enobosarm is small molecule and could be easily manufactured in those same plants(and sent in the same package) 9. Enobosarm could be co-formulated with Lilly’s drug to make a single pill where you lose weight, and 100% of it is fat: the holy grail of weight loss pills. 10. For any major GLP player, owning enobosarm for defensive purposes is just as important as owning it for offensive purposes per the reasons mentioned above.

1 · Reply

cray1965 Oct. 20 at 1:51 AM

$VERU Can someone stress test this for me, in case I’m off or missing something: 1. An oral muscle drug is a huge differentiator in the still early GLP gold rush, meaning whoever owns Enobosarm captures more new market share and steals market share from rivals. 2. Glps are moving to Oral. Enobosarm is the only oral muscle retention drug. Who would take an oral GLP and then an IV muscle retention drug. 3. Enobosarm could ultimately make more money for big pharma then even their GLPs because it has two uses(with GLP and maintenance) and can also be sold to all other GLPs for both of those uses, with no oral competition. 4. Veru is not acting(since final Phase 2 results) like a company that is actively promoting and shopping for funding as they run out of money. They are acting more like a company under NDA negotiations. 5. EOP2 changed the economics; bigger upside, less certainty, so it makes sense it would take longer to negotiate new terms even if they had been negotiating previously.

0 · Reply

QAZx666 Oct. 19 at 5:28 AM

$VERU Japan has a pandemic, what does that mean for Sabizabulin? https://www.nature.com/articles/d41586-025-03367-z

0 · Reply

QAZx666 Oct. 19 at 5:18 AM

$VERU Think Sabizabulin for those who did not get the right flu shots - https://www.nature.com/articles/d41586-025-03367-z

0 · Reply

cray1965 Oct. 19 at 4:15 AM

$VERU Would Lilly really sit back and let Novo/Regeneron/Roche/Astrazeneca fund the new trial and potentially prove the incremental weight loss? That would be the biggest strategic blunder of the last 20 years, for a company that is supposed to be visionary. I don't get it.

0 · Reply

Market Cap	55.70M
Revenue (ttm)	16.89M
Net Income (ttm)	-37.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.80%
Debt to Equity Ratio	0.00

Volume	110,100
Avg Vol	148,214
Day's Range	N/A - N/A
Shares Out	14.66M
Stochastic %K	13%
Beta	-0.75
Analysts	Strong Sell
Price Target	$16.33